Clinical Trial Update: An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects [Phase 1, Phase 2]

View source ↗

Summary

Exploratory Phase 1/2 trial of XP21279 with Lodosyn and Sinemet in Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• SINEMET (carbidopa and levodopa)
• XP21279 with Lodosyn

Snippet

Sponsor: XenoPort, Inc. | Conditions: Parkinson's Disease | Phase 1, Phase 2 | Status: COMPLETED